The FDA published a warning letter it sent to NSC Pearson over issues with the company’s Quotient ADHD being marketed as a consumer device to treat ADHD without the proper clearance. Pearson’s system, originally named the OPTAx system, was cleared with indications for use “as a device that provides clinicians with objective measurements of hyperactivity, […]